Forecasting the Economic Burden of Cardiovascular Disease and Stroke Through 2050: Enhanced Projection

This AHA presidential advisory projects cardiovascular disease and stroke costs through 2050 using a comprehensive economic modeling framework drawing on MEPS, Census data, and 2009–2019 prevalence trend data. The headline projections are definitive in their scale: CVD risk factor health care costs triple from $400 billion to $1.34 trillion; CVD condition costs nearly quadruple from $393 billion to $1.49 trillion; total CVD burden rises from $627 billion to $1.85 trillion — from 2.7% to 4.6% of US GDP.

Stroke carries the largest burden in both relative and absolute terms. At $357 billion in additional cost and a 535% relative increase, stroke represents the fastest-growing component of the CVD economic burden — yet it receives substantially less public attention than coronary heart disease. Coronary heart disease adds $323 billion. Heart failure adds $96 billion. These are not rounding errors; they are structural fiscal pressures that will dominate federal health spending over the next 25 years.

Subgroup projections sharpen the equity dimension. Asian American CVD costs are projected to rise 497%; Hispanic American costs 489% — driven largely by demographic growth, but also by persistent disparities in risk factor burden and access. Young adults (ages 20–44) face a 261% cost increase; the oldest adults (80+) face 371%. Medicare’s CVD costs climb from $384 billion to $1.2 trillion.

The per-person cost data establish the clinical context: each person with stroke costs $35,000 per year; each person with heart failure $18,000; each with coronary heart disease $13,000. Preventing a single case of stroke or CHD, sustained over years, generates substantial economic return on prevention investment — a calculation that should inform both clinical practice and policy design.

The analysis explicitly excludes the potential impact of GLP-1 agonists — an acknowledged limitation that could significantly alter the obesity and diabetes trajectories if those therapies achieve broad adoption. The modeling also excludes informal caregiving costs, which historical studies estimate at an additional 11% of direct costs.

We rate the evidence strong and the policy significance exceptional. This AHA presidential advisory, projecting US CVD costs to $1.85 trillion by 2050 (4.6% of GDP), with stroke and diabetes costs rising fastest, provides the most rigorous quantitative framework yet assembled for national cardiovascular prevention policy.